NEW DELHI — Scientists have used artificial intelligence (AI) tools to simplify a test that works for both hepatitis C and SARS-CoV-2, the virus that causes COVID-19.
[bsa_pro_ad_space id=1]The simplified test happens in one small test tube in just a few minutes. With further refinement, it could arrive at doctor's offices soon and, one day, become available as home tests that are as easy as a pregnancy test, the researchers said.
"We are trying to build a home-based test that is as reliable as a lab-based test," said Piyush Jain, a professor of chemical engineering at the University of Florida (UF) in the US.
"Our objective is to develop a simple test that eliminates the need for expensive equipment and provides results in just 10 to 20 minutes," said Jain, who led the research published in the journal Cell Reports Medicine.
The team is innovating on a system known as a one-pot reaction because the entire test happens in one small test tube. These tests, based on a technology known as RT-LAMP, can amplify small portions of a virus's genome and produce a visible signal when it detects the virus.
Reading these tests can be as simple as looking for a blue colour or using a small device that detects a change in the test tube, the researchers said.
The US Food and Drug Administration (FDA) has approved some at-home, one-pot tests for COVID-19, as a part of the emergency use authorisation, but they have a relatively high false positive rate, meaning they aren't as reliable as they could be.
"We are combining another technology called CRISPR to determine the difference between a false positive and a true positive," Jain said.
CRISPR has become known for its ability to drive rapid genetic engineering improvements, which have the potential to one day cure inherited diseases by repairing genomes.
Jain's group relies on the CRISPR system's ability to home in on particular genetic sequences. Only if the sequence for, say, the hepatitis virus is really present will the test show a positive result.
The RT-LAMP technology requires a temperature of 65.5 degrees Celsius while CRISPR works best at 37.7 degrees.
That difference makes tests far more complicated requiring two separate reactions too complicated for at-home use.
Jain's team has been trying to bridge this gap by developing a CRISPR system that can withstand higher temperatures. From a heat-loving species of bacteria, the researchers recently discovered a CRISPR enzyme that thrives at 60 degrees Celsius.
In their latest work, Jain's group turned to AI tools to analyse this enzyme and discover how they could make it survive at 65.5 degrees Celsius.
The AI programmes suggested a few dozen changes to the enzyme, which Jain's group tested in the lab. They eventually found four changes to the enzyme that let it work at 65.5 degrees.
"It's very challenging for any human to do this kind of analysis on an enzyme. We didn't have to spend years; we could make these improvements in months," Jain said.
"With everything working at the same temperature, now we are able to combine everything in a true one-pot reaction we call SPLENDID," he added.
The team verified their simplified SPLENDID test on clinical samples from patients with hepatitis C or COVID-19. The test was 97 per cent accurate for SARS-CoV-2 and 95 per cent accurate for the most prevalent version of the hepatitis C virus found globally.
Although it didn't work well against all other less predominant versions of the hepatitis C virus, straightforward changes to the test should quickly improve its accuracy, Jain added.